Caszyme is a gene editing company which combines its deep experience and dynamic platform to deliver world class CRISPR solutions. Caszyme was established in 2017 by Dr. Monika Paule, Dr. Giedrius Gasiunas and Prof. Virginijus Šikšnys – a pioneer of CRISPR-Cas gene editing research. Over the last 8 years, Caszyme has rapidly advanced its excellence and capabilities as an enabling expert partner in CRISPR gene editing solutions, collaborating with multiple life science organizations aiming to enter the CRISPR field or expand their gene editing capabilities. Company has a long-term expertise in discovery and development of novel gene editing tools, proteins evolution and engineering, mRNA synthesis and optimization. Also Caszyme has developed a platform of unique CRISPR nucleases. This enables Caszyme partners across various industries effectively apply CRISPR gene editing technology and tools for their market-ready products. Currently, in the therapeutics field Caszyme aims to develop safer and more compact gene editing tools for treating genetic eye diseases in vivo as well as develops a CRISPR based diagnostics platform. More information: caszyme.com